Genprex GNPX
- Market cap
- $1.5M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $4.6M+46% | $3.7M+10% | $3.3M−38% | $1.7M−58% | $2.8M−40% | $2.8M−24% | $2.5M−22% | $2.5M+50% | $2.2M−20% | $2.2M−23% | $2.7M+8% | $2.7M+7% |
| SG&A | $3.2M+5% | $2.3M−29% | $2.7M−31% | $4.8M+20% | $1.6M−51% | $1.5M−34% | $1.4M−47% | $2.2M−55% | $1.2M−26% | $1.3M−12% | $1.7M+22% | $1.8M−18% |
| −$7.8M+26% | −$6M−9% | −$6M−35% | −$6.5M−19% | −$4.3M−45% | −$4.3M−27% | −$4M−34% | −$4.7M−28% | −$3.3M−23% | −$3.5M−19% | −$4.5M+13% | −$4.5M−4% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$7.7M+26% | −$5.9M−9% | −$6M−35% | −$6.5M−19% | −$4.3M−44% | −$4.3M−27% | −$4M−34% | −$4.7M−28% | −$3.8M−12% | −$3.8M−13% | −$4.5M+13% | −$4.4M−5% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
EPS, diluted: 5 periods, Q4 FY17 to Q4 FY21: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY17 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Genprex's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GNPXGenprex | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| Peer median | $8.7M | 6.1× | 11.3× | 0.4× | −6% | 4.7% |
More on Genprex
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .